GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organogenesis Holdings Inc (NAS:ORGO) » Definitions » Gross Profit

Organogenesis Holdings (Organogenesis Holdings) Gross Profit : $326.9 Mil (TTM As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Organogenesis Holdings Gross Profit?

Organogenesis Holdings's gross profit for the three months ended in Mar. 2024 was $81.3 Mil. Organogenesis Holdings's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $326.9 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Organogenesis Holdings's gross profit for the three months ended in Mar. 2024 was $81.3 Mil. Organogenesis Holdings's Revenue for the three months ended in Mar. 2024 was $110.0 Mil. Therefore, Organogenesis Holdings's Gross Margin % for the quarter that ended in Mar. 2024 was 73.91%.

Organogenesis Holdings had a gross margin of 73.91% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 9 years, the highest Gross Margin % of Organogenesis Holdings was 76.71%. The lowest was 64.43%. And the median was 72.55%.


Organogenesis Holdings Gross Profit Historical Data

The historical data trend for Organogenesis Holdings's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organogenesis Holdings Gross Profit Chart

Organogenesis Holdings Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only 185.03 250.98 353.16 345.87 326.66

Organogenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.04 91.00 82.74 71.88 81.28

Competitive Comparison of Organogenesis Holdings's Gross Profit

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings's Gross Profit Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Gross Profit distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Gross Profit falls into.



Organogenesis Holdings Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Organogenesis Holdings's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=433.14 - 106.481
=326.7

Organogenesis Holdings's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=109.976 - 28.696
=81.3

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $326.9 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Organogenesis Holdings's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=81.3 / 109.976
=73.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Organogenesis Holdings  (NAS:ORGO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Organogenesis Holdings had a gross margin of 73.91% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Organogenesis Holdings Gross Profit Related Terms

Thank you for viewing the detailed overview of Organogenesis Holdings's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Organogenesis Holdings (Organogenesis Holdings) Business Description

Traded in Other Exchanges
Address
85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced wound care, surgical and sports medicine markets. Its product category includes Advanced Wound Care and Surgical and Sports Medicine. The company generates maximum revenue from Advanced Wound Care products. Some of its products include PuraPly Antimicrobial, Affinity, NuShield, Apligraf, Dermagraft and others.
Executives
Albert Erani 10 percent owner 150 DAN ROAD, 150 DAN ROAD, CANTON MA 01002
Michael W Katz 10 percent owner
Arthur S Leibowitz director 139 SOUNDVIEW DRIVE, PORT WASHINGTON NY 11050
Michael Joseph Driscoll director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gary S. Gillheeney director, officer: President and CEO C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gilberto Quintero director C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Michele Ilene Korfin director 17 STATE STREET, 7TH FLOOR, NEW YORK NY 10004
Antonio S. Montecalvo officer: VP Health Policy & Contracting C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Jon L Giacomin director 7000 CARDINAL PLACE, DUBLIN OH 43017
David Francisco officer: Chief Financial Officer C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Red Holdings, Llc 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Prathyusha Duraibabu director C/O SANGAMO THERAPEUTICS, INC., 501 CANAL BLVD., RICHMOND CA 94804
Glenn H Nussdorf director, 10 percent owner
Alan A. Ades director, 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021
Gn 2016 Organo 10-year Grat U/a/d September 30, 2016 10 percent owner C/O ORGANOGENESIS INC., 85 DAN ROAD, CANTON MA 02021

Organogenesis Holdings (Organogenesis Holdings) Headlines